Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

December 4, 2007

Last Updated Date

May 30, 2008

Start Date ^†

February 2007

Current Primary Outcome Measures ^†

Original Primary Outcome Measures ^†

Change History

Complete list of historical versions of study NCT00568282 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients

Official Title ^†

Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)

Brief Summary

The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

Detailed Description

The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.

Study Phase

Study Type ^†

Observational

Study Design ^†

Prospective

Condition ^†

Lung Cancer

Intervention ^†

Procedure: phlebotomy

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Recruiting

Enrollment ^†

100

Completion Date

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria:Inclusion Criteria (Cases):

Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC
Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection
ability to sign informed consent
at least 18 years of age

Inclusion Criteria (Controls):

no known prior or active malignancy
ability to sign informed consent
at least 18 years of age Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years

2. pregnant women

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Yes

Contacts ^††

Location Countries ^†

United States

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00568282

Responsible Party

Secondary IDs ^††

96710, LUN0017, NCT00568282

Study Sponsor ^†

Stanford University

Collaborators ^††

Investigators ^†

Principal Investigator:

Heather A. Wakelee

Stanford University

Information Provided By

Stanford University

Verification Date

May 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.